Current Firm
Atlas Venture
Focus
Biotech, Digital Health
David Grayzel is a physician-turned-venture capitalist at Atlas Venture who repeatedly co-founds and takes on CEO or chair roles at the biotech companies he backs, rather than staying purely on the investing side like most VCs. He specializes in immune system therapeutics and has co-founded multiple companies in areas like autoimmunity and oncology, including Surface Oncology, Q32 Bio, and Comanche Biopharma.
David Grayzel is a Managing Director, Atlas Venture at Atlas Venture, based in Cambridge, MA.
David's investment focus spans Biotech, Digital Health, primarily investing at the Seed, Series A stages. This specialization allows for deep domain knowledge and strong network effects that benefit portfolio companies.
David Grayzel is a Managing Director, Atlas Venture at Atlas Venture, based in Cambridge, MA. Their investment focus includes Biotech, Digital Health.
David Grayzel focuses on investments in Biotech, Digital Health through Atlas Venture. These focus areas reflect their domain expertise and the types of startups they actively seek to back.
David Grayzel is currently at Atlas Venture, headquartered in Cambridge, MA, serving as Managing Director, Atlas Venture.